This Project Grant award by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research to improve perioperative care for patients with opioid use disorder. The total award of $779,969 will be used to: Prospectively capture patient-reported pain and opioid use data among individuals with opioid use disorder undergoing common surgical procedures, to inform the adaptation of prescribing guidelines. Qualitatively assess the...
This $4.68 million project grant from the National Institute on Drug Abuse, part of the Department of Health and Human Services, will fund research under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The University of Michigan will conduct a prospective cohort study of 400 adults with opioid-involved polysubstance use in Michigan. Researchers will collect detailed weekly data on participants' substance use patterns and motivations over four weeks to understand nuanced profiles...
This federal Project Grant award from the National Institutes of Health (CFDA 93.279 - Drug Abuse and Addiction Research Programs) provides $1,105,489 to The Leland Stanford Junior University (Stanford University) to fund research aimed at reducing the risk of persistent postoperative opioid use and opioid use disorder among older adults undergoing inpatient surgery. The key products and services to be delivered under this 2-year grant include: Augmenting an existing dataset that links...
This federal Project Grant award, with a total funding amount of $2,542,500.00, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award supports the development of novel econometric research methods and a unified framework to integrate real-world evidence (RWE) into the analysis of inconclusive randomized controlled trials (RCTs) for opioid use disorder (OUD) treatments. This innovative approach aims to enhance the...
This $6,809,660 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke, under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to implement and investigate the efficacy and safety of a methadone-based standardized enhanced recovery after surgery (ERAS) protocol, as well as develop personalized ERAS protocols including precision methadone and oxycodone dosing, for the opioid-sparing management of surgical pain in children undergoing...
This $794,880 Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA 93.279 Drug Use and Addiction Research Programs, supports the development and implementation of a theory- and evidence-based intervention to enhance safe opioid disposal after surgery. The principal investigator, Dr. Lyen Huang at the University of Utah, will (1) evaluate the feasibility and acceptability of behavior change components to improve the university's current opioid disposal...
This federal Project Grant award, made by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to develop and evaluate a telemedicine-delivered digital cognitive behavioral intervention (DCBI) to decrease postoperative opioid use among patients undergoing total knee and hip arthroplasty. The key objectives of this 2-year project are to: 1) quantify the opioid-sparing properties of the...
This federal Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on investigating the co-use of cannabis and prescription opioids among emerging adults in medical settings. The $1,362,860 award, with an effective date of September 15, 2024 and an ultimate completion date of May 31, 2029, will support a prospective cohort study to examine the short- and long-term trajectories of opioid and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of a novel opioid adjuvant by Amalgent Therapeutics, Inc. The $220,668 award, spanning from August 1, 2024 to February 28, 2025, aims to further investigate the mechanism and efficacy of this adjuvant, which preliminary data indicates can increase the pain-relieving effects of opioids by at least 4-fold, allowing for...
This federal Project Grant award, titled "Cultivating Recovery: A Pilot Study of Digital Contingency Management for Co-Occurring Opioid and Alcohol Use Disorder", is sponsored by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $390,000 award to the Regents of the University of Michigan aims to pilot an innovative digital contingency management (CM) treatment delivered via mobile device to Medicaid beneficiaries with...